Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clene (CLNN)
NASDAQ:CLNN
Holding CLNN?
Track your performance easily
CLNN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.82 - $11.02
Previous CloseN/A
Volume48.08K
Average Volume (3M)87.38K
Market Cap
$39.02M
Enterprise Value$610.25M
Total Cash (Recent Filing)$8.79M
Total Debt (Recent Filing)$2.46M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Mar 31, 2025EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding7,979,726
10 Day Avg. Volume73,062
30 Day Avg. Volume87,381
Standard Deviation0.29
R-Squared0.00379
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)92.69
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap15.64
Enterprise Value/Revenue1.45K
Enterprise Value/Gross Profit1.14K
Enterprise Value/Ebitda-20.11
Forecast
1Y Price Target
$54.50Price Target Upside1037.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Clene News
PremiumCompany Announcements
Clene Secures $10M Debt Facility to Enhance Position
PremiumCompany Announcements
Clene Gains FDA Support for ALS Treatment Approval
PremiumCompany Announcements
Clene Announces Q3 2024 Results and ALS Drug Progress
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe confirmatory Phase 3 RESTORE-ALS trial aims to evaluate the effects of CNM-Au8 on survival and clinical worsening events in ALS, providing robust evidence for its efficacy.
FDA CollaborationClene's ongoing, significant dialogue with the FDA for the development of CNM-Au8 in ALS is a positive indication of potential favorable regulatory feedback.
Regulatory AdvancementsClene's CNM-Au8 has Orphan Drug Designation, qualifying it for a Priority Review by the FDA, enhancing its potential for accelerated approval.
Bears Say
Financial OutlookPushing potential launch out to 2026E means the price target goes to $83.
Market SentimentEarlier discussions with the agency have not been very encouraging for Clene, which has been reflected in negative stock moves.
Regulatory ApprovalThe FDA is still emphasizing NfL for approval, indicating additional data is required for CNM-Au8's approval.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLNN FAQ
What was Clene’s price range in the past 12 months?
Clene lowest stock price was $3.82 and its highest was $11.02 in the past 12 months.
What is Clene’s market cap?
Clene’s market cap is $39.02M.
When is Clene’s upcoming earnings report date?
Clene’s upcoming earnings report date is Mar 31, 2025 which is in 72 days.
How were Clene’s earnings last quarter?
Clene released its earnings results on Nov 13, 2024. The company reported -$1.22 earnings per share for the quarter, beating the consensus estimate of -$1.331 by $0.111.
Is Clene overvalued?
According to Wall Street analysts Clene’s price is currently Undervalued.
Does Clene pay dividends?
Clene does not currently pay dividends.
What is Clene’s EPS estimate?
Clene’s EPS estimate is -0.97.
How many shares outstanding does Clene have?
Clene has 7,979,726 shares outstanding.
What happened to Clene’s price movement after its last earnings report?
Clene reported an EPS of -$1.22 in its last earnings report, beating expectations of -$1.331. Following the earnings report the stock price went down -9.057%.
Which hedge fund is a major shareholder of Clene?
Currently, no hedge funds are holding shares in CLNN
---
Clene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.50 (1037.79% Upside)
$54.50 (1037.79% Upside)
Blogger Sentiment
Bullish
CLNN Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.72%
12-Months-Change
Fundamentals
Return on Equity
-416.92%
Trailing 12-Months
Asset Growth
-47.76%
Trailing 12-Months
Company Description
Clene
Clene is a clinical-stage biopharma company focused on developing and commercializing nanotherapeutics for the treatment of neurodegenerative disease.
---
CLNN Stock 12 Month Forecast
Average Price Target
$54.50
▲(1037.79% Upside)
Technical Analysis
Annovis Bio
―
Anavex Life Sciences
―
Brainstorm Cell Therapeutics
―
Cyclacel Pharmaceuticals
―
Genprex
―
Bluebird Bio
―
Best Analysts Covering CLNN
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-28.48%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -28.48% per trade.
---